News Image

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Provided By GlobeNewswire

Last update: May 14, 2025

Revenue for the First Quarter Ended March 31, 2025 was $13.1 million

Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025

Read more at globenewswire.com

FORTRESS BIOTECH INC

NASDAQ:FBIO (8/15/2025, 8:18:30 PM)

After market: 2.17 +0.05 (+2.36%)

2.12

+0.16 (+8.16%)


JOURNEY MEDICAL CORP

NASDAQ:DERM (8/15/2025, 8:15:37 PM)

After market: 6.3259 -0.62 (-8.98%)

6.95

-0.31 (-4.27%)



Find more stocks in the Stock Screener

Follow ChartMill for more